Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients

Background: Although useful in the time-race against COVID-19, CPAP cannot provide oxygen over the physiological limits imposed by severe pulmonary impairments. In previous studies, we reported that the administration of the SLAB51 probiotics reduced risk of developing respiratory failure in severe COVID-19 patients through the activation of oxygen sparing mechanisms providing additional oxygen to organs critical for survival. Methods: This “real life” study is a retrospective analysis of SARS-CoV-2 infected patients with hypoxaemic acute respiratory failure secondary to COVID-19 pneumonia undergoing CPAP treatment. A group of patients managed with ad interim routinely used therapy (RUT) were compared to a second group treated with RUT associated with SLAB51 oral bacteriotherapy (OB). Results: At baseline, patients receiving SLAB51 showed significantly lower blood oxygenation than controls. An opposite condition was observed after 3 days of treatment, despite the significantly reduced amount of oxygen received by patients taking SLAB51. At 7 days, a lower prevalence of COVID-19 patients needing CPAP in the group taking probiotics was observed. The administration of SLAB51 is a complementary approach for ameliorating oxygenation conditions at the systemic level. Conclusion: This study proves that probiotic administration results in an additional boost in alleviating hypoxic conditions, permitting to limit on the use of CPAP and its contraindications.

[1]  B. Long,et al.  Clinical update on COVID-19 for the emergency clinician: Airway and resuscitation , 2022, The American Journal of Emergency Medicine.

[2]  S. Jevtic,et al.  The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19 , 2022, Frontiers in Immunology.

[3]  J. Marcelin,et al.  COVID-19 Pathogenesis and Clinical Manifestations , 2022, Infectious Disease Clinics of North America.

[4]  P. Wischmeyer,et al.  Daily Lactobacillus Probiotic versus Placebo in COVID-19-Exposed Household Contacts (PROTECT-EHC): A Randomized Clinical Trial , 2022, medRxiv.

[5]  M. Olivares,et al.  Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial , 2022, Nutrients.

[6]  L. Bonfili,et al.  Strategic Modification of Gut Microbiota through Oral Bacteriotherapy Influences Hypoxia Inducible Factor-1α: Therapeutic Implication in Alzheimer’s Disease , 2021, International journal of molecular sciences.

[7]  T. Geisler,et al.  Platelets and COVID-19 , 2021, Hämostaseologie.

[8]  Kelly V. Ruggles,et al.  Platelets contribute to disease severity in COVID‐19 , 2021, Journal of Thrombosis and Haemostasis.

[9]  S. Ng,et al.  Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope? , 2021, Gastroenterology.

[10]  G. d’Ettorre,et al.  Oxygen Sparing Effect of Bacteriotherapy in COVID-19 , 2021, Nutrients.

[11]  Z. Bukumirić,et al.  Time Course of Redox Biomarkers in COVID-19 Pneumonia: Relation with Inflammatory, Multiorgan Impairment Biomarkers and CT Findings , 2021, Antioxidants.

[12]  A. Yoshizawa,et al.  Mammalian enteral ventilation ameliorates respiratory failure. , 2021, Med.

[13]  A. Muhammad,et al.  Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants , 2021, Frontiers in Cellular and Infection Microbiology.

[14]  E. N. Cavallari,et al.  Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study , 2021, Frontiers in Nutrition.

[15]  M. Kepinska,et al.  Human Nitric Oxide Synthase—Its Functions, Polymorphisms, and Inhibitors in the Context of Inflammation, Diabetes and Cardiovascular Diseases , 2020, International journal of molecular sciences.

[16]  M. Meschiari,et al.  Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT) , 2020, Clinical Microbiology and Infection.

[17]  I. Smith,et al.  Positive role of continuous positive airway pressure for intensive care unit patients with severe hypoxaemic respiratory failure due to COVID-19 pneumonia: A single centre experience , 2020, Journal of the Intensive Care Society.

[18]  V. Brusasco,et al.  Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure , 2020, European Respiratory Journal.

[19]  P. Halami,et al.  Role of probiotics to combat viral infections with emphasis on COVID-19 , 2020, Applied Microbiology and Biotechnology.

[20]  F. Blasi,et al.  Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study , 2020, European Respiratory Journal.

[21]  Xiandong Tao,et al.  SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients , 2020, Experimental Hematology & Oncology.

[22]  C. Scagnolari,et al.  Probiotics and COVID-19 , 2020, The Lancet Gastroenterology & Hepatology.

[23]  G. Rossi,et al.  Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19 , 2020, Frontiers in Medicine.

[24]  F. Di Marco,et al.  Severity of respiratory failure and outcome of patients needing a ventilatory support in the Emergency Department during Italian novel coronavirus SARS-CoV2 outbreak: Preliminary data on the role of Helmet CPAP and Non-Invasive Positive Pressure Ventilation , 2020, EClinicalMedicine.

[25]  Y. Shah,et al.  Oxygen battle in the gut: Hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine , 2020, The Journal of Biological Chemistry.

[26]  S. Pini,et al.  Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal , 2020, Journal of clinical medicine.

[27]  D. Dash,et al.  Platelet HIF-2α promotes thrombogenicity through PAI-1 synthesis and extracellular vesicle release , 2019, Haematologica.

[28]  Tomoyuki Ito,et al.  Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation , 2019, Antioxidants.

[29]  P. Artursson,et al.  Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues. , 2016, Advanced drug delivery reviews.

[30]  A. Polimeni,et al.  Anti-inflammatory effects of Lactobacillus brevis (CD2) on periodontal disease. , 2007, Oral diseases.

[31]  B. Brüne,et al.  Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation--implications for prolyl hydroxylase activity and iron. , 2005, Experimental cell research.

[32]  P. Fox,et al.  Arginine Catabolism by Sourdough Lactic Acid Bacteria: Purification and Characterization of the Arginine Deiminase Pathway Enzymes from Lactobacillus sanfranciscensis CB1 , 2002, Applied and Environmental Microbiology.

[33]  Tuba Kirci Torun,et al.  Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[34]  B. Mayer,et al.  Enzymatic function of nitric oxide synthases. , 1999, Cardiovascular research.

[35]  D. Shen,et al.  Effects of hypoxia on platelet activation in pilots. , 1994, Aviation, space, and environmental medicine.

[36]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).